Oppenheimer Upgrades Corbus Pharmaceuticals (CRBP) to Outperform; Sees ~150% Upside
Tweet Send to a Friend
(Updated - May 10, 2023 9:21 AM EDT)
Oppenheimer analyst Jeff Jones upgraded Corbus Pharmaceuticals (NASDAQ: CRBP) from Perform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Jeff Jones upgraded Corbus Pharmaceuticals (NASDAQ: CRBP) from Perform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
